Arbutus Biopharma Corp (ABUS) Holdings Reduced by Deutsche Bank AG

Deutsche Bank AG lowered its position in Arbutus Biopharma Corp (NASDAQ:ABUS) by 9.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 131,134 shares of the biopharmaceutical company’s stock after selling 14,154 shares during the period. Deutsche Bank AG’s holdings in Arbutus Biopharma were worth $501,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Legal & General Group Plc raised its position in shares of Arbutus Biopharma by 15.8% in the 4th quarter. Legal & General Group Plc now owns 28,407 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 3,867 shares in the last quarter. Rhumbline Advisers raised its position in shares of Arbutus Biopharma by 45.9% in the 4th quarter. Rhumbline Advisers now owns 49,032 shares of the biopharmaceutical company’s stock worth $188,000 after acquiring an additional 15,416 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Arbutus Biopharma by 116.2% in the 4th quarter. Two Sigma Investments LP now owns 52,344 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 28,133 shares in the last quarter. MetLife Investment Advisors LLC bought a new position in shares of Arbutus Biopharma in the 3rd quarter worth approximately $270,000. Finally, AQR Capital Management LLC raised its position in shares of Arbutus Biopharma by 142.3% in the 3rd quarter. AQR Capital Management LLC now owns 46,576 shares of the biopharmaceutical company’s stock worth $440,000 after acquiring an additional 27,354 shares in the last quarter. 43.96% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:ABUS opened at $2.33 on Wednesday. Arbutus Biopharma Corp has a 52-week low of $2.18 and a 52-week high of $12.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 12.75 and a quick ratio of 12.75. The company has a market capitalization of $134.17 million, a PE ratio of -2.28 and a beta of 1.61.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.16). Arbutus Biopharma had a negative net margin of 1,237.92% and a negative return on equity of 95.26%. The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.18 million. Equities research analysts forecast that Arbutus Biopharma Corp will post -1.32 EPS for the current year.

Several research analysts have recently issued reports on the company. Zacks Investment Research lowered Arbutus Biopharma from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. ValuEngine lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. BidaskClub raised Arbutus Biopharma from a “hold” rating to a “buy” rating in a research report on Tuesday, March 5th. Finally, Chardan Capital reissued a “buy” rating and issued a $6.50 target price on shares of Arbutus Biopharma in a research report on Sunday, March 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $6.25.

WARNING: “Arbutus Biopharma Corp (ABUS) Holdings Reduced by Deutsche Bank AG” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/22/arbutus-biopharma-corp-abus-holdings-reduced-by-deutsche-bank-ag.html.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Recommended Story: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Corp (NASDAQ:ABUS).

Institutional Ownership by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.